Long-term safety study of KL1333 for mitochondrial disease
Part of Hormones & metabolism clinical trials.
This is a follow-up study for patients who completed a previous trial (FALCON) testing KL1333, an experimental medicine for primary mitochondrial disease—a condition where cells don't produce enough energy. The study tracks how safe and effective the treatment remains over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier FALCON study and followed its rules closely
- You are 18 years old or older
- You can attend study visits on schedule and complete online questionnaires about how you feel
- Your other medications will stay the same throughout the study (if possible)
- You agree to stop taking idebenone (another mitochondrial disease medicine) during this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, sonlicromanol, to see if it can ease chronic fatigue and improve muscle function in people with a specific genetic condition called primary mitochondrial disease. If effective, it could offer a new treatment option to improve daily energy and quality of life.
This study tests a new medicine called ATI-105 in healthy adults to see if it is safe and how the body handles it. If you are generally healthy, you might be able to participate and help researchers learn more about this potential treatment.
This Phase 1 study tests a special MRI approach (using a contrast agent) to better measure changes in muscles in people with mitochondrial diseases. It also includes some healthy volunteers and other critically ill patients to compare results and check safety.
This Phase 2 trial tests a treatment made from deoxynucleosides to help people with mitochondrial depletion disorder caused by certain gene changes. If you match the genetic diagnosis, the study may see whether the treatment improves symptoms or disease markers.
This Phase 2 trial studies whether KL1333 improves chronic fatigue and muscle weakness in adults with a confirmed mitochondrial genetic disease. You may be eligible if you have persistent fatigue for at least 3 months and signs of muscle involvement, and can safely follow study requirements.
This study looks at brain chemicals in people with primary mitochondrial disease using an MRI scan. It aims to understand how the disease affects the brain and may help guide future treatments.
Hear when a new Mitochondrial Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.